# A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects

> **NCT03593278** · PHASE1 · COMPLETED · sponsor: **Viatris Innovation GmbH** · enrollment: 6 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ACT-246475

## Key facts

- **NCT ID:** NCT03593278
- **Lead sponsor:** Viatris Innovation GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-27
- **Primary completion:** 2018-08-05
- **Final completion:** 2018-08-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593278, "A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03593278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*